Research Paper – PC Lunwen http://pclunwen.com/ Sat, 15 Jan 2022 05:41:56 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://pclunwen.com/wp-content/uploads/2021/08/favicon.png Research Paper – PC Lunwen http://pclunwen.com/ 32 32 Sample Paper by Subject for Class 10, 12 Examination https://pclunwen.com/sample-paper-by-subject-for-class-10-12-examination/ Sat, 15 Jan 2022 05:41:56 +0000 https://pclunwen.com/sample-paper-by-subject-for-class-10-12-examination/ The CBSE has informed students in Class 10, 12 that there will be no changes to the CBSE Semester 2 exam pattern. The semester 2 exam is scheduled for March-April 2022. CBSE Term 2 Exam Date: Class 10,12 sample paper 2021-22 out at cbse.nic.in NEW DELHI: The Central Board for Secondary Education has released the […]]]>

The CBSE has informed students in Class 10, 12 that there will be no changes to the CBSE Semester 2 exam pattern. The semester 2 exam is scheduled for March-April 2022.

CBSE Term 2 Exam Date: Class 10,12 sample paper 2021-22 out at cbse.nic.in

NEW DELHI: The Central Board for Secondary Education has released the CBSE term 1 sample paper for class 10,12 2022 exam. Students can download the CBSE term 1 Class 10, 12 sample paper 2021-22 from the website official, cbse.gov.in. The CBSE is expected to hold second term board exams in March-April 2022. The dates for the CBSE class 12, 10 term 2 exams will be announced soon on cbse.nic.in.

advised: Start your JEE / NEET preparation with personalized AI-based coaching, follow the free path today Start now
advised: Click here for CBSE Class 12 Previous Year Sample Papers.

The CBSE class 10, 12 term 2 questions paper will have different formats such as case-based and situation-based short and long answer type. The CBSE 2nd term exam paper will last 2 hours.

The board recently informed students that there will be no new changes to the CBSE 2nd term exams and that the board will follow the pattern announced on July 5, 2021. The CBSE faced a barrage of criticism after an alleged last minute change in exam pattern, controversial pass and wrong answer key in the CBSE Term 1 2021 exam.

Meanwhile, CBSE Term 1 result for classes 10, 12 is also expected soon on cbseresults.nic.in. On January 11, the CBSE manager told Careers360 that the assessment process for the CBSE Class 10 and 12 exams is underway and the board will review the assessment process next week.

CBSE Term 2 Class 10, 12 sample questions 2021-22

Students can download the CBSE 10 and 12 class sample questions from cbseacademic.nic.in or using the link below.

CBSE Term 2 examples of Class 10 papers: Click here to download

CBSE Term 2 Class 12 sample papers: Click here to download

CBSE Term 2 2022 Sample Documents: How to Download

  • Visit CBSE official website – cbseacademic.nic.in
  • Click on the “Paper Sample Link” on the home page.
  • From the drop-down menu, select Class 10 or Class 12
  • Students can find the sample papers by subject and the grading scheme in PDF format
  • Click on the link provided for each topic to download the PDF

Follow us for the latest education news on colleges and universities, admission, courses, exams, schools, research, NEP and education policies and more.

To contact us, email us at news@careers360.com.


]]>
SOPHiA GENETICS Announces Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study | State https://pclunwen.com/sophia-genetics-announces-strong-traction-in-the-launch-phase-of-its-deep-lung-iv-multimodal-clinical-study-state/ Tue, 11 Jan 2022 12:27:00 +0000 https://pclunwen.com/sophia-genetics-announces-strong-traction-in-the-launch-phase-of-its-deep-lung-iv-multimodal-clinical-study-state/ BOSTON and LAUSANNE, Switzerland, January 11, 2022 / CNW / – SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data and knowledge sharing platform that advances data-driven medicine, today announced strong traction in the launch phase of its DEEP-Lung-IV clinical study (NCT04994795). Since its official launch last month, 12 sites in 5 countries […]]]>

BOSTON and LAUSANNE, Switzerland, January 11, 2022 / CNW / – SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data and knowledge sharing platform that advances data-driven medicine, today announced strong traction in the launch phase of its DEEP-Lung-IV clinical study (NCT04994795). Since its official launch last month, 12 sites in 5 countries have already registered to participate in the study.

Despite the clinical promises of immunotherapy, significant challenges remain as the majority of patients with non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors. Today, PD-L1 is the only standard predictive biomarker for the efficacy of immune checkpoint inhibitors, but it remains a very suboptimal biomarker with several well characterized problems limiting its clinical utility. Thus, there is an urgent need to discover new biomarkers predictive of response to immunotherapy. SOPHiA GENETICS ‘DEEP-Lung-IV clinical study relies on deep learning analysis of real-world multimodal data aggregation (including genomic, radiomic and clinical data) to identify and validate predictive signatures associated with the response to immunotherapy and the prognosis of patients with metastatic NSCLC (stage IV). Such signatures could help identify which patients may benefit from immunotherapy versus those who do not, as well as stratify patients based on risk, helping clinicians make more informed treatment decisions for their patients and supporting biopharma to ensure the right patients are selected for the clinic. testing.

The initial 12 sites that signed up to participate in the study include the Carbon Comprehensive Cancer Center in University of Wisconsin and Holden Comprehensive Cancer Center at University of Iowa Health Care in the United States, Public Assistance-Hospitals of Paris and Hospices Civils de Lyonnais in France, Leipzig University of Germany, Sunnybrook Health Sciences Center at Toronto, Canada, and Shaare Zedek Medical Center in Jerusalem, Israel, among others. Together, these sites are expected to contribute more than 2,000 of the 4,000 total patients targeted for enrollment during the study. 10 additional sites are awaiting integration in the first quarter of 2022, with more candidates expected to follow.

“We are very pleased with the strong traction since the launch of our multimodal DEEP-Lung-IV clinical study. The positive reception from participating sites highlights the great interest in unleashing the predictive potential of multimodal health data sets through large-scale real-world studies “said Dr Jurgi Camblong, co-founder and CEO of SOPHiA GENETICS. “We look forward to further accelerating this momentum in the first months of 2022.”

To learn more about the DEEP-Lung-IV clinical study, visit https://clinicaltrials.gov/ct2/show/NCT04994795.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for research in the life sciences. He is the creator of the SOPHiA DDM ™ platform, a cloud-based SaaS platform capable of analyzing data and generating information from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM ™ platform and associated solutions, products and services are currently used by more than 790 hospitals, laboratories and biopharmaceutical institutions around the world. For more information, visit SOPHiAGENETICS.COM, or log on to Twitter, LinkedIn and Instagram. Where others see data, we see answers.

SOPHiA GENETICS forward-looking statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements regarding our future results of operations and financial condition, business strategy, products and technology, and plans and objectives of management for future transactions, are forward-looking statements. . Forward-looking statements are based on the beliefs and assumptions of our management and on information currently available to our management. These statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in forward-looking statements due to various factors, including those described in our documents filed with the Securities and Exchange Commission. the United States. No assurance can be given that such future results will be achieved. These forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or commitment to update any forward-looking statements contained in this press release to reflect any change in our expectations or any change in the events, conditions or circumstances upon which such statements are based, unless it is required by law. No representation or warranty (express or implied) is made as to the accuracy of these forward-looking statements.

View original content to download multimedia: https://www.prnewswire.com/news-releases/sophia-genetics-reports-strong-traction-in-the-launch-phase-of-its-deep-lung-iv -multimodal -clinical-study-301457716.html

GENETIC SOURCE SOPHiA

]]>
Covid Updates: Number of Young Children in Hospital Who Tested Positive Jumps, CDC Says https://pclunwen.com/covid-updates-number-of-young-children-in-hospital-who-tested-positive-jumps-cdc-says/ Sun, 09 Jan 2022 15:54:55 +0000 https://pclunwen.com/covid-updates-number-of-young-children-in-hospital-who-tested-positive-jumps-cdc-says/ Dr Rochelle P. Walensky, director of the Centers for Disease Control and Prevention, in Washington in November. The agency has been criticized for its confused and opaque pandemic messages.Credit…Stefani Reynolds for The New York Times Dr Rochelle P. Walensky, director of the Centers for Disease Control and Prevention, defended the agency’s new guidelines on Friday […]]]>
Credit…Stefani Reynolds for The New York Times

Dr Rochelle P. Walensky, director of the Centers for Disease Control and Prevention, defended the agency’s new guidelines on Friday reducing the isolation period for people infected with the coronavirus to five days instead of 10, saying she was “science-based”.

Speaking in a sometimes controversial phone briefing with reporters, Dr Walensky also responded to criticism that the agency’s messages were muddled and opaque, saying she had participated in 80 White House briefings since. when he took up his duties and had sometimes answered several questions. times per week.

Friday’s press conference, conducted as the Omicron variant continues to generate a dramatic spike in coronavirus cases, was both rare and remarkable as the independent White House agency’s first briefing since the former President Donald J. Trump ended it in February 2020.

“I’ve heard that you want to hear from the CDC independently,” Dr Walensky said, adding that she expected the briefing to be the first in a long series. A number of journalists, seeking information about the complicated decisions made by the agency, thanked her repeatedly.

A highly regarded infectious disease expert with no government experience, Dr Walensky, who was appointed to lead the CDC early in the Biden administration, faced many challenges. The agency’s reputation and morale have been shaken by Trump’s White House, which has often tried to interfere with its scientific decisions.

Now the nation is heading into the third year of a pandemic with a virus which, Dr Walensky said, “has constantly thrown curveballs,” which has been grueling for healthcare workers and government officials. career at the forefront of the response.

“I think we are all proud to be serving the biggest and greatest public health crisis of our lives,” said one of these officials, Dr Henry Walke, director of the Division of Preparedness and Infections. Emerging CDC, who joined Dr. Walensky on the call. “So yeah, it’s exhausting. And it’s difficult, but good. Wow. I mean, this is the time to lean.

Dr. Walke’s presence on roll call was also unusual; Career scientists at the CDC have not participated in the press calls since Mr. Trump ended them. Mr Trump had become enraged, Dr Nancy Messonnier, then director of the CDC’s National Vaccination and Respiratory Disease Center, warned during a press briefing that the coronavirus would seriously disrupt the lives of Americans. Dr Messonnier left the CDC last year.

Dr Walensky has come under heavy criticism in recent days for a series of messaging missteps, the latest of which concerned the new isolation guidelines, released last week. Public health experts have criticized his failure to recommend that people infected with the virus test negative before ending the shortened five-day isolation period.

Dr Anthony S. Fauci, the president’s senior medical adviser on the pandemic, and Dr Vivek Murthy, the Surgeon General, have publicly opposed the CDC’s failure to include a test recommendation, further complicating the problem. This week, the CDC clarified that if people had access to the tests, they could take them.

CNN reported Friday that Dr Walensky had requested media training this fall; a spokesperson for the agency noted that this was “not unusual” for agency directors. And Dr. Walensky herself said she was “committed to continuing to improve as we learn more about science and to communicate that to all of you” and the public.

At Friday’s briefing, Dr Walensky faced a barrage of sometimes conflicting questions, including confusion over the advice and its scientific rationale. She said it was based on a scientific review of dozens of articles analyzing the infectivity of the coronavirus, although she admitted many of them were based on variants other than Omicron.

She said it would be weeks before scientists had detailed laboratory data for Omicron – including data showing whether people infected with the highly transmissible variant can become infected again.

“We have indications that if you have had Delta you are likely to be infected with Omicron,” she said, referring to the earlier Delta variant of the virus. But, she said, there is no data yet to suggest “that Omicron is protecting against Omicron.”


Source link

]]>
Global Filtration Papers Market Study and Forecast -2030 https://pclunwen.com/global-filtration-papers-market-study-and-forecast-2030/ Fri, 07 Jan 2022 23:20:40 +0000 https://pclunwen.com/global-filtration-papers-market-study-and-forecast-2030/ Understanding the influence of COVID-19 on the Filtration Papers Market with our analysts monitoring the situation around the world. Description of the report: Market Strides published a report titled Filtration Papers Market by Type, Application, Regional Analysis, Growth Opportunity, and Industry Forecast 2022-2030. The Filtration Papers market report provides a comprehensive overview including the current […]]]>

Understanding the influence of COVID-19 on the Filtration Papers Market with our analysts monitoring the situation around the world.

Description of the report:

Market Strides published a report titled Filtration Papers Market by Type, Application, Regional Analysis, Growth Opportunity, and Industry Forecast 2022-2030. The Filtration Papers market report provides a comprehensive overview including the current scenario and the prospects for future growth. The Filter Papers market report analyzes various factors and trends for the coming years and the key factors driving the growth and demand for this market are analyzed in detail in this report.

Some of the major players in the global filtration papers market are GE Healthcare
Sartorius
Thermo Fisher Scientific
Ahlstrom
Carolina Organic Supply
Eisco Laboratories
Frymaster
Henny penny
Labconco
Microclar
Pitco
Houston Science Equipment

Request a sample report: https://marketstrides.com/request-sample/filtration-papers-market

Research methodology

Our research methodology is a blend of secondary and primary research that ideally begins with exhaustive data mining, conducting primary interviews (suppliers / distributors / end users) and formulating ideas, estimates and rates. growth accordingly. Final primary validation is a mandate to confirm our research results with key opinion leaders (KoLs), industry experts, filtration papers include key supplies, and independent consultants, among others.

Market segmentation

The Filter Papers market is segmented on the basis of type, application, end-use industry, region, and country.

Global Filtration Papers Market By Type

Qualitative filter papers
Quantitative filtration papers

The Filter Papers market sub-segment is expected to hold the largest market share during the forecast period. Growing concern about the market and the industry is expected to drive the filtration papers market.

Global Filtration Papers Market By Application

F&B
Pharmaceuticals and biotechnology
food and drinks
Health care
Automotive
Others

Filtration paper application valves are one of the most fundamental and indispensable components of today’s modern technological society. The market segment is expected to hold the largest market share in the global filtration papers market.

By region:

 North America (United States, Canada)
 Europe (United Kingdom, Germany, France, Italy)
 Asia Pacific (China, India, Japan, Singapore, Malaysia)
 Latin America (Brazil, Mexico)
 Middle East and Africa

Buy Global Filtration Papers Market Report 2022-2030: Choose the license type

What is the significance of this report?

  • Comprehensive global and regional analysis of Filtration Papers markets.
  • Comprehensive coverage of all market segments in Filtration Papers markets to analyze trends, global market development and market size forecast from 2030.
  • Comprehensive analysis of companies operating in the global market. Company Profile includes Product Portfolio Analysis, Sales, SWOT Analysis and Latest Developments.
  • The Growth Matrix analyzes the product segments and regions that market players need to pay attention to in order to invest, integrate, grow and / or diversify.

The main content of the report:

  • Detailed analysis of the parent market.
  • Significant changes have taken place in key aspects of the market.
  • Detailed analysis of market segmentation.
  • Market analysis of previous, current and forecast periods in terms of value and quantity.
  • Market share analysis of filtration papers.
  • Assessment of niche markets.
  • The main practices of market players.
  • The main suggestion is to increase the influence of the company in the market.

Check the discount for this report: https://marketstrides.com/check-discount/filtration-papers-market

About Us:

Market Strides is a global market intelligence aggregator and publisher research reports, equity reports, database directories and economic reports. Our repository is diverse, covering virtually all industrial sectors and even more so each category and sub-category within the industry.

Perhaps our pre-integration strategy for publishers is what sets us apart in the market. The publishers and their market research reports are meticulously validated by our internal panel of consultants, before a feature on our website. These groups of internal consultants are also responsible for ensuring that our website only presents the most up-to-date reports.

Do you have a question ? Ask our experts

Market Strides has a professional team that assists you in many advanced industry specific trends, content and tests different strategies and implements the most productive for the business.

For more information, E-mail – [email protected]

Contact us: +1 856 677 8909 (United States)

Follow us on social media:

Facebook || LinkedIn || Twitter || Pinterest || Tumblr || Instagram || Average

Filtration Papers Market, Filtration Papers Market 2022, Filtration Papers Market Scope, Filtration Papers Market Opportunity, Filtration Papers Market Research, Filtration Papers Market Price, Papers Market Sales Filtration, Filtration Papers Market Key Regions, Filtration Papers Manufacturing, Filtration Papers Industry Growth, Filtration Papers Industry Revenue, Filtration Papers Market Trends, Papers Market Size Filtration Papers, Filtration Papers Market Analysis, Filtration Papers Market Share, Filtration Papers Market Growth, Filtration Papers Market Demand, Industry Trends



Source link

]]>
Electronic Paper Market Research Report (2021 – 2028) Key Trends and Opportunities https://pclunwen.com/electronic-paper-market-research-report-2021-2028-key-trends-and-opportunities/ Thu, 06 Jan 2022 09:46:27 +0000 https://pclunwen.com/electronic-paper-market-research-report-2021-2028-key-trends-and-opportunities/ “ Global Market Vision has added effective statistical data to its repository, titled as Electronic paper market. This report gives a comprehensive overview of the market, covering various aspects such as product definitions as well as its vendors. The competitive landscape of various industries is measured on the basis of regions and income. To get […]]]>

Global Market Vision has added effective statistical data to its repository, titled as Electronic paper market. This report gives a comprehensive overview of the market, covering various aspects such as product definitions as well as its vendors. The competitive landscape of various industries is measured on the basis of regions and income. To get a better outlook on the global electronic paper market, relevant table and graphs are included in the report. Different factors are behind the growth of industries.

Request to obtain a sample report: to know the impact of COVID-19 on this industry @ https://globalmarketvision.com/sample_request/40270

Global reach of electronic paper and market size

The e-Paper market is segmented by company, region (country), type, and application. Players, stakeholders and other participants of the global e-Paper market will be able to gain the upper hand by using the report as a powerful resource. The segmental analysis focuses on the revenue and forecast by type and by application in terms of revenue and forecast for the period 2021-2028.

The major market players presented in the report include:

E Ink, Liquavista, OED Technologies, LG Display, Qualcomm, Pervasive Displays, Plastic Logic.

Market segmentation :

Based on type:

Electrophoretic display (EPD), electrowetting (EWD), electrofluidic (EFD), others

Based on demand:

Consumer electronics, Medical, Transport, Others

The assessment provides 360 ° view and insights – outlining key findings of the Electronic Paper Market, current scenario analysis that highlights the downturn aims to deliver unique strategies and solutions by tracking and comparing strategies of the main players. In addition, the study helps to better understand the competition of emerging players to better understand the companies and make more informed decisions.

A cohesive market research report like the Electronic Paper Market report expands the scope of success in business. All data and statistics included in the report are backed up by well-known analysis tools that include SWOT analysis and Porter’s five forces analysis. The market research carried out in this report is very thoughtful and helps companies to make better decisions and develop superior strategies in production, marketing, sales and promotion. Market definition, market segmentation, key market developments, competitive analysis, and research methodology are the major chapter of this E-Paper Market report which is again drawn up precisely and specifically.

Geographically, the detailed analysis of the consumption, revenue, market share and growth rate of the following regions:

  • North America (United States, Canada, Mexico)
  • Asia-Pacific (China, India, Japan, Taiwan, South Korea, Australia, Indonesia, Singapore, Malaysia, rest of Asia-Pacific)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, rest of Europe)
  • Central and South America (Brazil, Argentina, rest of South America)
  • Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Rest of Middle East and Africa)

Reasons to buy:

  • Get insight, analysis and strategic insight from competitors to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Rank new customers or potential partners into the target demographic.
  • Develop tactical initiatives by understanding the areas of intervention of large companies.
  • Plan meritorious mergers and acquisitions by identifying the best manufacturer.
  • Formulate corrective actions for pipeline projects by understanding the depth of the e-Paper pipeline.
  • Develop and design licensing and licensing strategies by identifying potential partners with the most attractive projects to improve and expand business potential and reach.
  • The report will be updated with the latest data and will be delivered to you within 2-4 business days of ordering.
  • Suitable for supporting your internal and external presentations with reliable and high quality data and analysis.
  • Create regional and national strategies based on local data and analyzes.

Table of Contents (TOC):

Chapter 1 Introduction and overview

Chapter 2 Industry cost structure and economic impact

chapter 3 Rising trends and new technologies with the main key players

Chapter 4 Global Electronic Paper Market Analysis, Trends, Growth Factor

Chapter 5 Application of the electronic paper market and commercial activity with potential analysis

Chapter 6 Global Electronic Paper Market Segment, Type, Application

Chapter 7 Global Electronic Paper Market Analysis (by Application, Type, End User)

Chapter 8 Analysis of the major key vendors of the electronic paper market

Chapter 9 Trend of analysis development

Chapter 10 Conclusion

Get a research report within 48 hours @ https://globalmarketvision.com/checkout/?currency=USD&type=single_user_license&report_id=40270

If you have any special requirement, please let us know and we will offer the report to you at a custom price.

The final report will add the analysis of the Impact of Covid-19 in this Electronic Paper Market report.

Adapting to the recent new COVID-19 pandemic, the impact of the COVID-19 pandemic on the global electronic paper market is included in this report. The influence of the novel coronavirus pandemic on the growth of the e-Paper market is analyzed and described in the report.

About Global Market Vision

Global Market Vision is made up of an ambitious team of young, experienced people who focus on the details and deliver the information according to the client’s needs. Information is vital in the business world and we specialize in disseminating it. Our experts not only have in-depth expertise, but can also create a comprehensive report to help you grow your own business.

With our reports, you can make important tactical business decisions with the confidence that they are based on accurate and well-founded information. Our experts can allay any concerns or doubts about our accuracy and help you tell the difference between reliable and less reliable reports, reducing the risk of making decisions. We can make your decision-making process more precise and increase the likelihood of your goals succeeding.

Contact us

Sarah Ivans | Business development

Phone: + 1-3105055739

E-mail: [email protected]

Global market vision

Website: www.globalmarketvision.com


Source link

]]>
Vaccinex Announces the KEYNOTE B84 Phase Ib Combined Study of Keytruda® and Pepinemab in Patients … | Nation / World https://pclunwen.com/vaccinex-announces-the-keynote-b84-phase-ib-combined-study-of-keytruda-and-pepinemab-in-patients-nation-world/ Tue, 04 Jan 2022 13:03:14 +0000 https://pclunwen.com/vaccinex-announces-the-keynote-b84-phase-ib-combined-study-of-keytruda-and-pepinemab-in-patients-nation-world/ The phase 1b segment assessed the safety and tolerability of the combination Paving the way for expansion and acceleration of enrollments in the Phase 2 segment of the study ROCHESTER, NY, January 04, 2022 (GLOBE NEWSWIRE) – Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to the treatment […]]]>

The phase 1b segment assessed the safety and tolerability of the combination

Paving the way for expansion and acceleration of enrollments in the Phase 2 segment of the study

ROCHESTER, NY, January 04, 2022 (GLOBE NEWSWIRE) – Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to the treatment of cancer and neurodegenerative diseases by inhibition of SEMA4D, today announced positive intermediate safety data in the phase Ib “safety run-in” segment of the KEYNOTE B84 combination study from Keytruda® (Merck, NYSE: MRK, known as MSD name outside the United States and Canada) and pepinemab (Vaccinex) in patients with advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (R / M HNSCC). The Phase 2 segment of the study is now expected to begin recruitment and is expected to accelerate patient accumulation.

The phase Ib “safety run-in” segment of the trial (NCT04815720) aimed to assess the safety and tolerability of pipinemab (20 mg / kg) in combination with Keytruda (anti-PD-1 treatment from Merck, pembrolizumab, 200 mg Q3W / every three weeks) to determine a recommended phase 2 dose (RP2D) for the dose extension phase of the study enrolling patients with R / M HNSCC. The interim safety analysis has been completed by the Data Safety Monitoring Board and signals the start of the Phase 2 expansion segment.

“We are very pleased that interim safety data for KEYNOTE B84 has indicated that the combination of pipinemab and Keytruda appears to be well tolerated,” said Maurice Zauderer, Ph.D., President and CEO. “Vaccinex hopes that the combination of pipinemab and anti-PD-1 therapy for the treatment of advanced R / M HSNCC may improve the benefits for patients. There is a strong rationale for the development of HNSCC as these tumors express very high levels of SEMA4D and we believe that preclinical data has indicated that this contributes to the pathology of the disease. We look forward to making progress in recruiting the Phase 2 segment of the trial. “

About the KEYNOTE B84 study:

The KEYNOTE B84 combined study of Keytruda® (anti-PD-1 treatment by Merck, pembrolizumab) and pepinemab (SEMA4D inhibitory monoclonal antibody by Vaccinex) is underway for the first-line treatment of patients with squamous cell carcinoma. advanced, recurrent or metastatic head and neck (R / M HNSCC). The study has two parts:

  • Segment 1: The final segment of Phase 1b “Preparing for Safety” assessed the safety and tolerability of the combination and defined a Phase 2 Recommended Dose (RP2D) in 3 to 6 subjects. After recruiting the first three subjects, the Data Safety Monitoring Board determined that the RP2D dose of pipinemab (20 mg / kg) and Keytruda (200 mg Q3W) was safe and well tolerated.
  • Segment 2: The “expansion” segment of Phase 2 is now expected to begin recruiting up to 62 subjects at 19 trial sites in the United States. The main objective of this segment is to assess the objective response rate (ORR) by response endpoint in solid tumors (RECIST) 1.1 of the combination in immunotherapy-naïve patients with R / M Advanced HNSCC.

The secondary objectives of the study are to assess progression-free survival (PFS) according to RECIST 1.1, overall survival (OS) and duration of response (DOR).

The study is also expected to assess a number of exploratory measures including pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of the combination and a number of biomarkers and genomic tumor signatures.

Additional information on the study is available at the following address: KEYNOTE B84 Link clinictrials.gov. Vaccinex anticipates interim results for the primary efficacy endpoint, ORR, in the second half of 2022.

Vaccinex will sponsor the study which is being carried out in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc.

Vaccinex owns the global commercial and development rights for pipinemab.

Keytruda® is a registered trademark of Merck.

About Pépinémab

Pepinemab is a humanized IgG4 monoclonal antibody that inhibits SEMA4D, which regulates chronic inflammation in the tumor microenvironment. Preclinical / clinical data show that pepinemab promotes infiltration / activation of dendritic cells / CD8 + T cells and reverses immunosuppression within the tumor.

The results of a phase 1b / 2 study to evaluate the combination of pipinemab with a checkpoint inhibitor, BAVENCIO®, (with Merck KGaA) were presented by Dr. Shafique, MD, assistant professor of thoracic oncology , Moffitt Cancer Center, in an oral poster and discussion at ASCO 2020 and was featured in the July 2021 publication from Clinical Cancer Research. Vaccinex reported that the results of the Phase 1b / 2 CLASSICAL-Lung trial showed an overall response rate (ORR) of 25 to 33% for patients with difficult-to-treat weak / negative PD-L1 tumors treated with association, while ORR has been reported for similar patients. treated with anti-PD-L1 monotherapy is approximately 10 to 15%. The study report also indicated that pipinemab did not increase the immune toxicities of BAVENCIO, but increased the penetration of cytotoxic T cells. The publication is available electronically at: Clinical cancer research.

About Vaccinex, Inc.

Vaccinex, Inc. is pioneering a differentiated approach to the treatment of cancer and slowly progressing neurodegenerative diseases through the inhibition of 4D semaphorin (SEMA4D). The Company’s lead drug candidate, pipinemab, blocks SEMA4D, a potent biological effector that it claims prevents immune infiltration into tumors and triggers chronic inflammation in the brain. The Company also intends to leverage its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations, in particular by leveraging its unique ability to select antibodies. of high value against important multi-pass membrane receptors including GPCR and ion channels.

Forward-looking statements

To the extent that the statements contained in this presentation are not descriptions of historical fact concerning Vaccinex, Inc. (“Vaccinex”, “we”, “us” or “our”), they are forward-looking statements reflecting the current management beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives regarding the results and timing of our clinical trials of pipinemab in various indications, the use and potential benefits of pipinemab in Huntington’s disease. and Alzheimer’s and other indications, and other statements identified by words such as “may”, “will”, “will appear”, “expect”, “hope”, “planned”, “anticipate” “,” Estimate “,” intend “,” hypothesis “,” “potential”, “suggest”, “advance” and similar expressions or their negative aspects (as well as other words and expressions referring to future events, conditions or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the results of our preclinical research and development programs, clinical development programs, results to fu trends, performances or achievements differ materially from those expressed or implied by forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to our reliance on our flagship product candidate, pepinemab, the impact of the COVID-19 pandemic. , and other matters which could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section entitled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission ( “SEC”) and the other risks and uncertainties described in the Company’s most recent year-end annual report on Form 10-K and subsequent filings with the SEC.

Investor contact

John mullaly

LifeSci Advisors, LLC

617-429-3548

jmullaly@lifesciadvisors.com


Source link

]]>
New Studies Strengthen Belief Omicron Is Less Likely to Damage Lungs | Omicron variant https://pclunwen.com/new-studies-strengthen-belief-omicron-is-less-likely-to-damage-lungs-omicron-variant/ Sun, 02 Jan 2022 10:32:00 +0000 https://pclunwen.com/new-studies-strengthen-belief-omicron-is-less-likely-to-damage-lungs-omicron-variant/ A growing body of evidence indicates that the Omicron Covid variant is more likely to infect the throat than the lungs, which scientists say could explain why it appears to be more infectious but less fatal than other versions of the virus. Six studies – four published since Christmas Eve – have shown that Omicron […]]]>

A growing body of evidence indicates that the Omicron Covid variant is more likely to infect the throat than the lungs, which scientists say could explain why it appears to be more infectious but less fatal than other versions of the virus. Six studies – four published since Christmas Eve – have shown that Omicron does not damage people’s lungs as much as the Delta and other previous variants of Covid. The studies have yet to be evaluated by other scientists.

“The result of all the mutations that differentiate Omicron from previous variants is that it may have altered its ability to infect different types of cells,” said Deenan Pillay, professor of virology at University College London.

“Essentially, it seems to be more capable of infecting the upper respiratory tract – the cells in the throat. It would therefore multiply more easily in cells than in deep lung cells. It’s really preliminary but the studies are going in the same direction.

If the virus produces more cells in the throat, this makes it more transmissible, which would help explain the rapid spread of Omicron. A virus that does infect lung tissue well, on the other hand, will be potentially more dangerous but less transmissible.

Researchers at the University of Liverpool’s Molecular Virology Research Group published a preprint on Boxing Day that shows Omicron causes “less severe disease” in mice, according to Professor James Stewart. The article showed that mice infected with Omicron lose less weight, have a lower viral load, and suffer from less severe pneumonia.

“It’s a piece of the puzzle,” he said. “The animal model suggests the disease is less severe than Delta and the original Wuhan virus. It appears to be cleared more quickly and the animals have recovered faster, which is linked to the clinical data that is reaching us.

“The first indications are that this is good news, but it is not a signal to lower your guard, because if you are clinically vulnerable the consequences are still not great – there are deaths from Omicron. Not everyone can rip off their masks and party.

The Neyts Lab at the University of Louvain in Belgium found similar results in Syrian hamsters, with a lower viral load in the lungs compared to other variants. Professor Johan Neyts said this could be because the virus infects humans better than hamsters, or is more likely to infect the upper respiratory tract, or because it causes less severe illness.

Some research has suggested that lateral flow tests detect Omicron better when the throat is swabbed rather than the nose. Photograph: Gareth Everett / Huw Evans / Rex Shutterstock

Another pre-print, submitted to Nature last week by researchers in the United States, also found that mice with Omicron lost less weight and had a lower viral load. And researchers at the University of Glasgow’s Virus Research Center have found evidence that Omicron has changed the way it enters the body. Omicron was likely to bypass immunity in people who received two doses of the vaccine, but a booster dose resulted in “partial restoration of immunity.”

Christmas’s extensive research builds on a University of Hong Kong study last month showing fewer Omicron infections in the lungs, and research by Professor Ravi Gupta of the University of Cambridge, including the The team studied blood samples from vaccinated patients. They found Omicron able to escape vaccines, but less able to enter lung cells.

The latest scientific research comes amid a debate over how best to perform home tests. Last week, some scientists suggested that lateral flow tests (LFT) might be more accurate if people took swabs from the throat as well as the nose. Professor Jennifer Rohn of University College London said her experience using LFTs was that she had tested negative using nasal swabs but positive when taking a sample from her throat.

This appeared to be corroborated by a study from South Africa showing that saliva samples subjected to PCR tests were better than nasal swabs at detecting Omicron.

However, Professor Lawrence Young, a virologist at the University of Warwick, said the study was not large enough that any conclusions could be drawn. “This is a small study of patients with acute symptoms who were not hospitalized. On the one hand, this confirms previous studies indicating that saliva testing could be useful as an easier sampling approach to perform. I don’t think this study is meaningful enough to conclude anything about Omicron’s behavior.

The UK Health Safety Agency said there was no indication the rapid tests differed in their ability to detect Omicron or Delta variants, although the tests were continuously monitored by researchers. “All lateral flow devices used by NHS Test and Trace have gone through rigorous validation and have been shown to be very effective at detecting Covid-19 in people,” a spokesperson said. “We are currently seeing a high number of positive lateral flow device tests reported. This means that we are detecting tens of thousands of cases that might otherwise have gone unnoticed. “


Source link

]]>
SINTX Technologies (SINT) announces the transition of its Scientific Director https://pclunwen.com/sintx-technologies-sint-announces-the-transition-of-its-scientific-director/ Fri, 31 Dec 2021 14:05:47 +0000 https://pclunwen.com/sintx-technologies-sint-announces-the-transition-of-its-scientific-director/ Receive instant alerts for news on your actions. Claim your 1-week free trial for Street Insider Premium here. SINTX Technologies, Inc. (NASDAQ: SINT), an original equipment manufacturer of advanced ceramics, today announced that its Scientific Director, Dr. Bryan J. McEntire, will retire at the end of 2021 after 17 years with the company. Dr Ryan […]]]>

Receive instant alerts for news on your actions. Claim your 1-week free trial for Street Insider Premium here.


SINTX Technologies, Inc. (NASDAQ: SINT), an original equipment manufacturer of advanced ceramics, today announced that its Scientific Director, Dr. Bryan J. McEntire, will retire at the end of 2021 after 17 years with the company. Dr Ryan Bock will serve as Vice President of Research and Development (R&D) to lead SINTX’s R&D activities. After his retirement, Dr McEntire will continue to support SINTX Technologies in the role of Chief Scientist Emeritus.

Dr McEntire has worked in the advanced ceramic industry for 46 years and has co-authored over 130 technical papers and presentations on ceramic materials, their processing and characterization. While at SINTX, he was responsible for research and development, product development, testing and validation, manufacturing and quality control of orthopedic implants made from silicon nitride. Prior to joining SINTX, McEntire held various executive positions at notable ceramics and materials companies including Applied Materials, Saint-Gobain Industrial Ceramics Corporation, Norton / TRW Ceramics and Ceramatec. He was elected a Fellow of the American Society in 2012 and was a guest speaker on ceramic training at the American Ceramic Society Annual Meeting from 1986 to 1995.

“Dr. McEntire has been a tremendous asset and a friend of SINTX for almost two decades,” said Dr. Sonny Bal, President and CEO of SINTX Technologies. “While we are sad to see him go, we are delighted that he continues to be involved through an advisory role. “

“It has been both a privilege and a pleasure to work with and for the great men and women of SINTX in the development of advanced ceramic solutions for the biomedical, industrial, aerospace and armor markets,” said Dr. Bryan J. McEntire. “I could not have ended my career with a more admirable organization, endowed with strong management leadership and exceptional technical and manufacturing talent. I wish them all the best in their future endeavors, and hope to be of assistance to them in my new role as advisor.

Currently Director of R&D, Dr Bock will continue his biomaterial development efforts in addition to expanding application-oriented research to antipathogenic and technical ceramic products as he assumes the role of Vice President of R&D when Dr McEntire will retire. Dr Bock has supported SINTX through a variety of roles for 13 years and has extensive experience in advanced ceramics, colloid and surface science, and biomaterials.

“I look forward to leading SINTX’s R&D efforts, which include rich collaborations with academic and industrial research groups around the world, as well as focused and application-oriented research carried out by our skilled and dedicated in-house team,” said Dr Ryan Bock, Director of R&D. , SINTX Technologies. “It has been my great honor to have Dr. McEntire as a mentor and colleague for many years of biomaterials development activities, including the discovery of new properties of silicon nitride that allow SINTX to deliver differentiated products in a ever increasing variety of market spaces. His expertise and advice will be greatly appreciated as we continue to find new applications for advanced ceramic materials. “


Source link

]]>
Bank of Japan: (Research Paper) Zombies, again? COVID-19 Business Support Programs in Japan https://pclunwen.com/bank-of-japan-research-paper-zombies-again-covid-19-business-support-programs-in-japan/ Thu, 30 Dec 2021 05:27:02 +0000 https://pclunwen.com/bank-of-japan-research-paper-zombies-again-covid-19-business-support-programs-in-japan/ December 30, 2021Takeo hoshi* 1Daiji kawaguchi* 2Kenichi ueda* 3 Summary We designed and conducted an enterprise-level survey on the use of government programs related to COVID-19, in collaboration with Tokyo Shoko Research, LTD (TSR). By combining the survey results with the financial statements of the responding companies, we investigated the factors underlying the award of […]]]>

December 30, 2021
Takeo hoshi* 1
Daiji kawaguchi* 2
Kenichi ueda* 3

Summary

We designed and conducted an enterprise-level survey on the use of government programs related to COVID-19, in collaboration with Tokyo Shoko Research, LTD (TSR). By combining the survey results with the financial statements of the responding companies, we investigated the factors underlying the award of various government programs. We find that businesses that had low credit scores before the COVID-19 pandemic were more likely to apply for and receive the grants and concessional loans offered by the Japanese government in 2020. Businesses with low credit scores do not are not necessarily zombies, which are defined as businesses that are not viable but kept alive with the help of creditors and / or the government. Our result suggests that government aid may also have subsidized some underperforming companies that were not yet zombies before the pandemic.

We thank Tasuku Sato, Saisawat Samutpradit and Ryuji Sugioka for their excellent research assistance, Tokyo Shoko Research, LTD (TSR) for implementing the online survey, and Masahiro Odaka and Satoshi Takahashi of the Japan Finance Corporation ( JFC) for responding to our inquiries regarding concessional loan programs. We also appreciate the feedback we received from Midori Ookawa, Kei Takahashi, Tsutomu Miyagawa, Iichiro Uesugi and participants at the macroeconomics workshop at Waseda University, the ABFER Capital Market Development webinar, and the Center’s 9th joint conference. for Advanced Research in Finance (CARF) at the University of Tokyo and the Research and Statistics Department of the Bank of Japan. All remaining errors are ours. We acknowledge financial support from CARF, Japan Agency for Science and Technology Grant (JPMJRX18H3), and Scientific Research Assistance Grants (Kakenhi 20H00071).

  1. * 1University of Tokyo
    Email: thoshi@eu-tokyo.ac.jp
  2. * 2University of Tokyo
    Email: kawaguchi@eu-tokyo.ac.jp
  3. * 3University of Tokyo
    Email: uedak@eu-tokyo.ac.jp

Note

The papers in the Bank of Japan Working Paper Series are released to stimulate discussion and comment. The opinions expressed are those of the authors and do not necessarily reflect those of the Bank.
If you have any comments or questions on the Working Paper Series, please contact each author. When making a copy or reproduction of the content for commercial purposes, please contact the Bank’s public relations department (post.prd8@boj.or.jp) in advance to request permission. When copying or reproducing, the source, Bank of Japan Working Paper Series, must be explicitly mentioned.

Warning

Bank of Japan published this content on December 30, 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on December 30, 2021 05:26:03 AM UTC.


Source link

]]>
Major documents of the 10th and 12th plus; CBSE Program, Term 1 CBSE Result Date Time, OMR Sheet, Notes – What Next? https://pclunwen.com/major-documents-of-the-10th-and-12th-plus-cbse-program-term-1-cbse-result-date-time-omr-sheet-notes-what-next/ Tue, 28 Dec 2021 06:22:00 +0000 https://pclunwen.com/major-documents-of-the-10th-and-12th-plus-cbse-program-term-1-cbse-result-date-time-omr-sheet-notes-what-next/ CBSE Result Term 1: CBSE has successfully completed Class 10 and Class 12 major exams. In this article, we have published some important observations from our board experts. Created on: Dec 28, 2018 2021 11:52 IST Examination of the board of directors of the CBSE 2022 (term 1): main documents of the 10th and 12th; […]]]>

CBSE Result Term 1: CBSE has successfully completed Class 10 and Class 12 major exams. In this article, we have published some important observations from our board experts.

Created on: Dec 28, 2018 2021 11:52 IST

Examination of the board of directors of the CBSE 2022 (term 1): main documents of the 10th and 12th; And after?

CBSE Result Term 1: The Central Council for Secondary Education (CBSE) successfully organized the main CBSE grade 10 and 12 exams for the first quarter of 2021-22. The students wonder about the CBSE result (term 1), the score, the date and the time of the CBSE result of quarter 1. However, no official announcement was made by the board of directors about the result. CBSE of the first trimester. However, based on the conversation with our experts, here’s what students can expect.

Term 1 CBSE Result:

No official announcement regarding CBSE 1st semester results has been announced by the board, however, it is expected that the board will be able to announce the score of the 1st semester CBSE 10th and 12th 2021-22 exams in January. The final CBSE score (with Pass / Fail status, final grades, etc.) will be announced by the board following the second trimester board exams of the CBSE.

CBSE Board of Directors 2021-22 Review: Download Q1 Q&A Documents in PDF; Check expert response key

CBSE 10th Board Exam 2021-22: Download Semester 1 question papers in PDF; Check expert response key

Verification process: CBSE board reviews for period 1 2021-22

Numerous media have already reported that the CBSE will be releasing online student response sheets (OMR sheet) that students can access through their credentials, likely in January. Media houses have also indicated that access will be free. Our experts hope that the verification process may begin soon.

CBSE Program (Term 2):

The CBSE semester 2 program is already live on the CBSE academic website. Jagran Josh has also published the Term 2 CBSE Syllabus 2021-22. It can be accessed from the link below.

CBSE Program: 9, 10, 11, 12 – Revised and Reduced (Term 2 and 1 – Combined): Science, Commerce, Arts!

Sample CBSE paper for session 2:

Every year, the CBSE publishes sample papers for the 10 and 12 months before the board exams start so that students can easily get acquainted with the latest exam template. According to the board’s provisional plan, the board exams for Semester 2 CBSE 10th and 12th, 2022 could take place in March. Therefore, the board is expected to release sample CBSE documents for Quarter 2 in January.

These are some of the important things that our experts suggest that could be present in the next council plan. Students can also check out other important resources available in Jagran Josh’s school section for preparation for the next CBSE Board Exam in Quarter 2 2022.

NCERT Solutions for Class 10 (All Subjects): Important for CBSE Term 2 2022 Exam

NCERT Solutions for Class 12: Download PDF

Play Jagran

गेम्स खेलें और जीतें एक लाख रुपए तक कैश


Source link

]]>